To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Urology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
DURANCEDURANCE: A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr | |
---|---|
Local Project Reference: | 121881 |
Principal Investigator: | Dr. Mark Linch |
Drug Class/ Treatment: | Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody) + S-488210/S-488211 (Peptide Vaccine) |
Patient Population: | Non-Muscle Invasive Bladder Cancer |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
ABACUS-2ABACUS-2: Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer | |
---|---|
Local Project Reference: | 135538 |
Principal Investigator: | Dr. Mark Linch |
Drug Class/ Treatment: | Atezolizumab (IgG1 Isotype Monoclonal Antibody against PD-L1) |
Patient Population: | Patient requiring surgery with:
|
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
EPICEPIC Trial: A Phase II Trial of Cemiplimab alone or in combination with Standard of Care Chemotherapy in Locally Advanced or Metastatic Penile Carcinoma | |
---|---|
Local Project Reference: | 126549 |
Principal Investigator: | Dr. Constantine Alifrangis |
Drug Class/ Treatment: | Cemiplimab (Humanised Monoclonal IgG4 Antibody Targeting PD-1/PD-L1 Pathway) Monotherapy or Combination with SOC Chemotherapy |
Patient Population: | Non-Muscle Invasive Bladder Cancer |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
POTENTIA (CBT307-1)A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours (POTENTIA) | |
---|---|
Local Project Reference: | 129679 |
Principal Investigator: | Dr. Anuradha Jayaram |
Drug Class/ Treatment: | CB307 (Trispecific Humabody T-Cell Enhancer) |
Patient Population: | PSMA+ (IHC) Advanced or Metastatic Solid Tumours |